Novartis AG Files Q1 2025 Financial Report
Ticker: NVSEF · Form: 6-K · Filed: Apr 29, 2025 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, quarterly-results
TL;DR
Novartis dropped its Q1 2025 financials, check the 6-K for the numbers.
AI Summary
Novartis AG filed a Form 6-K on April 29, 2025, reporting its Q1 2025 financial results. The filing includes Exhibit 99.1, a Financial Report for Q1 2025, and Exhibit 99.2, a Condensed Financial Report. Paul Penepent, Head of Financial Reporting and Accounting, signed the report.
Why It Matters
This filing provides investors with the latest financial performance data for Novartis AG, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant risk factors.
Key Players & Entities
- Novartis AG (company) — Registrant
- Paul Penepent (person) — Head Financial Reporting and Accounting
- April 29, 2025 (date) — Filing date
- 20250331 (date) — Period of report
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report Novartis AG's Q1 2025 financial results, including a Financial Report for Q1 2025 and a Condensed Financial Report.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on April 29, 2025.
Who signed the Form 6-K on behalf of Novartis AG?
Paul Penepent, Head of Financial Reporting and Accounting, signed the Form 6-K on behalf of Novartis AG.
What exhibits are included with this filing?
This filing includes Exhibit 99.1 (Financial Report Q1 2025) and Exhibit 99.2 (Condensed Financial Report).
What is the period of report for the financial information provided?
The period of report for the financial information provided is March 31, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2025 by Paul Penepent regarding NOVARTIS AG (NVSEF).